Ultragenyx is trading 5.8% higher at $15.25, with no clear company-specific catalyst identified for the move.

  • Recent coverage centers on the FAYUVI FDA approval announced September 17, rather than a new announcement on September 29.
  • Broader indices are mixed and modestly lower or flat, and do not clearly explain Ultragenyx’s gain.